

# ACOLYTE BIOMEDICA

□ As increasing resistance to antibiotics drives concern about infectious diseases rapidly up the global health agenda, a new diagnostic system has slashed lead times from days to just a few hours, boosting treatment success and cutting costs substantially. In the \$1.3 billion clinical microbiology market, Acolyte Biomedica's newly-launched BacLite® platform has transformed the competitive framework and its prospective applications run much wider...

## □ AT A GLANCE

- Established by ANGLE in 2000
- IP originally developed by the UK's Porton Down based Defence Science & Technology Laboratory
- First product, BacLite® Rapid MRSA test, launched in May 2005

## □ CONTACT DETAILS


Acolyte Biomedica Ltd  
Building 227  
Porton Down Science Park  
Salisbury  
Wiltshire  
SP4 0JQ

T: +44 (0)1980 551320  
F: +44 (0)1980 551321  
E: spohara@acolytebiomedica.com  
www.acolytebiomedica.com

## □ ABOUT ANGLE

Founded in 1994, ANGLE is an international Consulting, Management and Ventures company focusing on the commercialisation of technology and the development of technology-based industry.

ANGLE Ventures funds, develops and operates its own technology-based businesses. Utilising our in-house Progeny® process, we commercialise intellectual property developed by technology partners in the academic, private and public sectors.



In the UK, the spread of MRSA has generated many headlines and created much controversy. It is, however, just one manifestation of a much broader global issue. Increasing resistance to antibiotics means that infectious diseases have re-emerged as a serious health issue across the world. In the UK alone, for example, hospital-acquired infections cause an estimated 5000 patient deaths per annum. The problem of diagnosis is exacerbated greatly by the traditional manually-intensive bacteriological process of culturing organisms. As a result, a long (two to four days) lead time is required for diagnosis. Worse: 45-90 per cent of current provisionally-assessed broad spectrum anti-biotic treatments are inappropriate.

Founded by ANGLE in 2000, Acolyte Biomedica addresses this critical issue. Its platform technology, BacLite®, slashes the lead time to diagnose and provide successful antibiotic therapy from days to just five hours.

It also delivers two other key benefits. First, its widespread application should reduce the spread of resistant organisms and, consequently, extend the life of available antibiotics. Second, it helps healthcare providers reduce costs by minimising hospital stays, cutting levels of secondary testing and facilitating continued use of less expensive antibiotics.

BacLite® is based on IP originally developed by the UK's Porton Down based Defence





BacLite® is ideally positioned to address many established and emerging needs across the whole domain of life sciences

Science & Technology Laboratory (Dstl). It benefits from 13 years' investment by the UK's Ministry of Defence in AK Rapid® diagnostics technology. AK itself is a highly sensitive marker enzyme used to detect low levels of cell numbers such as biological warfare agents.

## MARKET OPPORTUNITY

The market 'canvas' for Acolyte's proprietary diagnostic systems and research reagents in clinical microbiology is huge. It is estimated today at \$1.3 billion.

In human terms this means, for example, 140,000 UK MRSA infections and a staggering 5 million MRSA tests (15m in the USA) per annum. As rapid testing is adopted for active surveillance, these levels will almost certainly rise sharply.

More broadly, BacLite® is ideally positioned to address many established and emerging needs across the whole domain of life sciences.

## ACOLYTE TODAY AND IN THE FUTURE

Following successful testing at Salisbury, Southampton, Barts and other London hospitals, Acolyte launched BacLite® Rapid MRSA in May 2005 as the first step in a world-wide roll-out.

Beyond MRSA screening, Acolyte has already demonstrated BacLite's® full applicability to septicaemia detection and Antibiotic Sensitivity Testing (AST) and the firm is developing a BacLite® suite. Looking ahead, Acolyte anticipates extending application to embrace the majority of hospital microbiology workload.

## ACOLYTE MANAGEMENT TEAM

### *Tim Coombs*

B.Sc., Ph.D.,

Executive Chairman

(J & J, Graseby, Dade Behring, Whatman)

### *Steve O'Hara*

MBA, MSc, MIBiol

Director of Microbiology

(Manager, Southampton Public Health laboratory)

### *Keith Bowhill*

MBA, FCCA,

Head of Finance

(Anagen, IDG, Icen)

### *Nick Foote*

B.A., Ph.D

Development Manager

(Enzymatix Ltd, Celsis plc)

### *John Hockley*

B.Sc, Post Grad Dip Medical Micro.,

Manufacturing Manager

(Veterinary Laboratories Agency, Merial Animal Health Ltd)

## ACOLYTE BIOMEDICA AND ANGLE

Acolyte Biomedica was one of the first demonstrations of the power of ANGLE's Progeny® process which is designed to help companies commercialise the value of their intellectual property. In total, Acolyte has raised £6.42 million from ANGLE and venture capitalists. ANGLE, which retains a 11% stake in Acolyte, is itself a category pioneer, leader and expert in technology wealth creation (TWC). Spanning the worlds of technology, finance and management, it applies this core expertise in three ways to:

- Enable companies to participate effectively in TWC (Management Services);
- Help firms decide how to optimise and progress the value of their engagement in TWC (Consulting); and finally, as with Acolyte, to
- Deliver successful direct results from TWC (Ventures).

